Mental Health Clinics in New Oxford, PA Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Voices In Bloom Aba, Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 189 Oxford Blvd, New Oxford, PA 17350 Phone: 717-253-6967 Fax: 844-430-0219 |
Lincoln Intermediate Unit 12 Psychologist Medicare: Not Enrolled in Medicare Practice Location: 65 Billerbeck St, New Oxford, PA 17350 Phone: 717-624-4616 Fax: 717-624-6523 |
Turtle Cove Counseling, Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 92 Irish Dr, New Oxford, PA 17350 Phone: 443-617-6854 Fax: 717-479-5571 |
Lori A Miley Licensed Psychologist Pllc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3585 Carlisle Pike, New Oxford, PA 17350 Phone: 717-624-1334 Fax: 717-624-1992 |
Equality Counseling Services, Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 550 Turkey Pit Rd, New Oxford, PA 17350 Phone: 717-465-9100 |
The Lehman Center Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 343 Lincoln Way W, New Oxford, PA 17350 Phone: 717-624-4461 |
News Archive
Intercell to acquire Cytos' platform technology for monoclonal antibody discovery
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
Ipsen launches Decapeptyl LP 22.5 mg in France
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Varenicline may increase risk of adverse cardiovascular events among smokers
The use of varenicline to stop smoking is associated with a 72% increased risk of a serious adverse cardiovascular event, states an article in CMAJ.
Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
› Verified 9 days ago